Proprotein convertase subtilisin kexin type 9 (pcsk9) deletion but not inhibition of extracellular pcsk9 reduces infarct sizes ex vivo but not in vivo

HIGHLIGHTS

• who: Rolf Schreckenberg and colleagues from the Institute of Physiology, Faculty of Medicine, Justus-Liebig University, Gieu00dfen, Gieu00dfen, Germany have published the Article: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo, in the Journal: (JOURNAL) of 10/06/2022
• what: Collectively, this analysis shows that ischemic events increase the cardiac expression of PCSK9 and subsequently affect the local concentration of extracellular PCSK9. The experiments described in Figure 2 were newly performed according to the established protocol (see experiments in Figure . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.